Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates

Core Viewpoint - Apellis Pharmaceuticals reported a quarterly loss of $0.29 per share, which was better than the Zacks Consensus Estimate of a loss of $0.39, and an improvement from a loss of $0.73 per share a year ago, indicating a positive earnings surprise of 25.64% [1] Financial Performance - The company achieved revenues of $212.53 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 8.46%, and showing a significant increase from $146.38 million in the same quarter last year [2] - Over the last four quarters, Apellis has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Apellis Pharmaceuticals shares have declined approximately 18.5% since the beginning of the year, contrasting with the S&P 500's slight decline of -0.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.37 on revenues of $197.1 million, and for the current fiscal year, it is -$1.06 on revenues of $853.11 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Apellis belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]